Innovative Natural Killer Extracellular Vesicle Therapeutics for Hard-to-Treat Cancers.
Vanquish Biologics is advancing a scalable NKEV platform designed for infusion-based treatment of aggressive and refractory cancers. Indications include glioblastoma multiforme, pancreatic cancer, multiple myeloma, triple-negative breast cancer, and other difficult malignancies.
Preclinical toxicity studies completed with Southern Research.
Stability program and regulatory planning underway toward pre-IND engagement with FDA.
Scalable manufacturing strategy aligned to GMP transition and clinical supply readiness.
Supported by non-dilutive funding including NCI STTR and Innovate Alabama programs.
Alabama translational footprint anchored through Southern Research and Station 41 presence.
A Cell-Derived Therapeutic Platform Designed for Access and Scale.
Vanquish Biologics is developing natural killer cell-derived extracellular vesicles, or NKEVs, as an off-the-shelf biologic therapy intended to combine tumor-directed activity with immune activation in a formulation suitable for infusion-center delivery. The company’s platform is designed around a scalable product format, including powder-based shipment, site formulation, and IV administration pathways intended to support broader access than highly specialized cell therapies.
Why NKEVs
Dual mechanism: direct anti-tumor activity plus activation of endogenous NK responses.
Off-the-shelf format rather than patient-specific cell collection.
Infusion-center compatible workflow using conventional oncology delivery settings.
Broad applicability across refractory solid and hematologic malignancies.
Focus Indications
GBM High unmet need in aggressive brain cancer; part of current strategic focus.
Pancreatic cancer Core translational priority and featured in NCI proposal language.
Multiple myeloma Strong historic program basis and continuing relevance in refractory disease.
TNBC Difficult solid tumor setting with legacy preclinical inclusion in company materials.
AML / refractory hematologic cancers Fits your “difficult refractory cases” framing and earlier materials.
Other difficult cancers Reserved phrasing for expansion beyond lead indications.
Development Status
Completed
Preclinical toxicity studies completed.
Underway
Stability studies completed or underway, depending on what you want publicly stated; your March 2026 deck says pending while your April 2026 final report states strong progress with analytical and toxicity milestones, so this needs harmonization before publishing.
Underway
Pre-IND planning and FDA engagement scheduling underway.
Underway
GMP manufacturing transition planning in progress.
Planned
GLP IND-enabling studies planned with Southern Research.
Not Started
IND filing and early clinical studies as next major milestones.
Vanquish Biologics is building its translational path through collaborations spanning preclinical development, grant-backed innovation, and manufacturing scale-up, including work with Southern Research, support linked to Innovate Alabama programs, and non-dilutive NCI STTR funding.
.avif)
Confidential Manufacturing Partner
Manufacturing Readiness
The company is preparing for GMP-grade scale-up through a manufacturing strategy designed around reproducibility, analytical control, and clinical supply readiness, supported by an active confidential CDMO relationship and a broader CMC plan tied to IND-enabling execution.
Partner with Us
Request a corporate overview or invest in Vanquish